Novo Nordisk draws mixed views on Wall Street after guidance cut

Novo Nordisk (NVO) significantly lowered its 2025 sales and operating profit growth outlook for the second time this year, citing market headwinds and pressure on its GLP-1 obesity drug franchise from compounded versions, which sent its stock down ~22%. The revised currency-adjusted outlook now stands at 8-14% for sales and 10-16% for operating profit. In response, Bank of America and Barclays downgraded NVO due to concerns over its GLP-1 business, pipeline, and leadership transition, while some Seeking Alpha analysts maintained Buy ratings, viewing the selloff as an overreaction given solid long-term fundamentals and current undervaluation.

Analysis

Novo Nordisk (NVO) is facing significant investor concern following a second downward revision of its 2025 guidance, which triggered a stock decline of approximately 22%. The company now projects currency-adjusted sales growth of 8%-14% and operating profit growth of 10%-16%, a sharp reduction from its May guidance. Management attributes the revision to intensifying pressure on its flagship GLP-1 obesity drug franchise, specifically from compounded versions marketed by competitors like Hims & Hers. This negative development prompted downgrades from major sell-side institutions; Bank of America moved to a Neutral rating with a price target cut to DKK 375, while Barclays downgraded to Equal Weight, citing heightened GLP-1 business risks, a challenged late-stage pipeline, and uncertainty around a leadership transition. In contrast, a segment of analysts, particularly from Seeking Alpha, posits that the market's reaction is excessive. They maintain a Buy rating, arguing that the company's long-term fundamentals remain solid and that the current, lower valuation presents a compelling entry point despite the evident near-term headwinds.

Key Decisions for Investors

• Investors should scrutinize the dual downgrades from Bank of America and Barclays, which signal institutional concern over competitive erosion in the GLP-1 market and weakness in NVO's product pipeline.
• Contrarian investors may view the 22% stock price correction as a buying opportunity, aligning with the thesis that the selloff is an overreaction and that the company's long-term growth trajectory remains undervalued.
• It is critical to monitor upcoming quarterly reports for hard data on Wegovy sales volumes and pricing to assess the real-world impact of compounded alternatives on NVO's core franchise.
• Given the conflicting analyst opinions and heightened uncertainty, investors may consider trimming positions to manage risk or await further clarity on the leadership transition and pipeline developments before committing new capital.